Skip to content

Randomized crossover study of the efficacy of wIRA in treatment of sacroiliitis of male patients with ankylosing spondylitis

Randomized crossover study of the efficacy of wIRA in treatment of sacroiliitis of male patients with ankylosing spondylitis

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-INR-17012682
Enrollment
Unknown
Registered
2017-09-15
Start date
2017-09-14
Completion date
Unknown
Last updated
2017-10-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ankylosing spondylitis/AS

Interventions

Contral Group:NSAIDs
wIRA Group:NSAIDs+wIRA

Sponsors

Department of Rheumatology and Immunology, Shengli Oilfield Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: 1. Confirmed ankylosing spondylitis by Modified New York criteria for ankylosing spondylitis (1984); 2. Aged more than 16 years old; 3. At least one active inflammatory region of the sacroiliac joint confirmed by MR; 4. To be able to conscious, understand and express Chinese; 5. Volunteer to participate in the study.

Exclusion criteria

Exclusion criteria: (1) Fever; (2) Uncontrolled hypertension; (3) Diabetes; (4) Skin ulceration in sacroiliac joint region; (5) Severe liver and kidney and heart insufficiency; (6) active ulcer of the digestive tract within 3 months; bleeding in gastrointestinal within 6 months; (7) Received the treatment of biological agents within 3 months; (8) Other conditions that is considered to be not suitable for participate the study.

Design outcomes

Primary

MeasureTime frame
BASDAI;Pain-VAS;

Secondary

MeasureTime frame
Morningstiffness-VAS;RI;

Countries

China

Contacts

Public ContactZHANG QI

Shengli Oilfield Central Hospital

drzhangqi@126.com+86 13864731972

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026